

Antibody-[®]drug conjugates: Smart chemotherapy deli

Ca-A Cancer Journal for Clinicians

72, 165-182

DOI: [10.3322/caac.21705](https://doi.org/10.3322/caac.21705)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation. <i>Seminars in Cancer Biology</i> , 2022, 86, 899-913.	4.3	30
2	Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022, 24, 809-817.	1.8	35
3	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	1.6	63
4	Cetuximab-Polymersome-Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers. <i>Biomacromolecules</i> , 2022, 23, 100-111.	2.6	12
5	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 106, 102395.	3.4	60
6	Antibody-drug conjugates: beyond current approvals and potential future strategies. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 252-277.	0.5	11
7	Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1227-1235.	1.9	13
8	Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.. <i>American Journal of Cancer Research</i> , 2022, 12, 1671-1685.	1.4	0
9	Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	14
10	Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. <i>Biomarker Research</i> , 2022, 10, .	2.8	42
11	Research Progress of Antibody-Drug Conjugate Therapy for Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
12	Advances in Diagnosis and Therapy for Bladder Cancer. <i>Cancers</i> , 2022, 14, 3181.	1.7	16
13	Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold. <i>Bioconjugate Chemistry</i> , 2022, 33, 1241-1253.	1.8	13
14	Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. <i>Cancers</i> , 2022, 14, 3996.	1.7	24
15	Clinical applications of mass spectrometry-based proteomics in cancer: Where are we?. <i>Proteomics</i> , 2023, 23, .	1.3	20
16	Current Analytical Strategies for Antibody-Drug Conjugates in Biomatrices. <i>Molecules</i> , 2022, 27, 6299.	1.7	6
17	Pharmaindustrie: Zytostatika zum Patienten bringen. <i>Nachrichten Aus Der Chemie</i> , 2022, 70, 34-36.	0.0	0
18	Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1801-1819.	1.8	7

#	ARTICLE	IF	CITATIONS
19	The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors. <i>Cancer Research</i> , 2022, 82, 3659-3661.	0.4	5
20	Antibody-Drug Conjugates and Tissue-Agnostic Drug Development. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 462-468.	1.0	0
21	Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. <i>Cancer</i> , 2023, 129, 283-295.	2.0	27
22	Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
23	Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma. <i>Biomolecules</i> , 2022, 12, 1744.	1.8	3
24	Nectins and Nectin-like Molecules in Colorectal Cancer: Role in Diagnostics, Prognostic Values, and Emerging Treatment Options: A Literature Review. <i>Diagnostics</i> , 2022, 12, 3076.	1.3	2
25	A mild phenoxyethyl linker for self-immolative release of antibody-drug conjugates. <i>Chinese Chemical Letters</i> , 2023, 34, 108091.	4.8	1
26	The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Annals of Translational Medicine</i> , 2023, 11, 27-27.	0.7	0
27	Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
28	Degradable Antibody Conjugates: Emerging New Modality. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 140-148.	2.9	11
29	Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2023, 55, 101795.	3.2	7
30	HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era. <i>European Journal of Cancer Prevention</i> , 2023, 32, 149-154.	0.6	2
31	Recent progress of aptamer-drug conjugates in cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1358-1370.	5.7	18
32	Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. <i>Cancers</i> , 2023, 15, 1130.	1.7	7
33	Myxoid Liposarcomas: Systemic Treatment Options. <i>Current Treatment Options in Oncology</i> , 2023, 24, 274-291.	1.3	3
34	The evolving landscape of antibody-drug conjugates in gynecologic cancers. <i>Cancer Treatment Reviews</i> , 2023, 116, 102546.	3.4	13
35	Phenyldivinylnsulfonamides for the construction of antibody-drug conjugates with controlled four payloads. <i>Bioorganic Chemistry</i> , 2023, 134, 106463.	2.0	3
36	Future potential targets of antibody-drug conjugates in breast cancer. <i>Breast</i> , 2023, 69, 312-322.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Natural peptides for immunological regulation in cancer therapy: Mechanism, facts and perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114257.	2.5	14
38	Antibodyâ€“drug conjugates: in search of partners of choice. <i>Trends in Cancer</i> , 2023, 9, 339-354.	3.8	44
39	Anti-GD2 immunoliposomes loaded with oxamate for neuroblastoma. <i>Pediatric Research</i> , 0, , .	1.1	0
40	Antiâ€“HER2 scFvâ€“nCyt <i>c</i> â€“Modified Lipidâ€“Encapsulated Oxygen Nanobubbles Prepared with Bulk Nanobubble Water for Inducing Apoptosis and Improving Photodynamic Therapy. <i>Small</i> , 0, , 2206091.	5.2	0
41	Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. <i>Pharmaceutics</i> , 2023, 15, 938.	2.0	1
42	Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. <i>Cell Research</i> , 2023, 33, 389-402.	5.7	13
43	Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. <i>Archives of Pharmacal Research</i> , 2023, 46, 361-388.	2.7	9
44	â€“Targetingâ€™ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancerâ€”An Updated Review. <i>Current Oncology</i> , 2023, 30, 4329-4350.	0.9	1
45	Purified fluorescent nanohybrids based on quantum dotâ€“HER2â€“antibody for breast tumor target imaging. <i>Talanta</i> , 2023, 260, 124560.	2.9	2
86	Current challenges and practical aspects of molecular pathology for non-small cell lung cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	1.4	3
101	The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1
105	Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions. <i>Archives of Pharmacal Research</i> , 2024, 47, 40-65.	2.7	1
107	Multifunctional nanoparticle-mediated combining therapy for human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	7.1	2